838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
TJ Stone, J Beardsley, J Johnson, C Ohl… - Open Forum …, 2020 - academic.oup.com
Background CARs are first line agents for serious infections caused by ESBL producers.
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …
838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
TJ Stone, J Beardsley, J Johnson, C Ohl… - Open Forum …, 2020 - ncbi.nlm.nih.gov
Background CARs are first line agents for serious infections caused by ESBL producers.
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …
838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
T Stone, J Beardsley, J Johnson, C Ohl… - Open Forum …, 2020 - europepmc.org
Background CARs are first line agents for serious infections caused by ESBL producers.
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …
Likelihood of developing subsequent ESBL infection is unknown. In patients (pts) with a …